Sites Grátis no Comunidades.net
100 Teses Publicadas Phosphorylethanolamine

ARTIGOS CIENTÍFICOS PUBLICADOS EM FAVOR DA

 

FOSFOETANOLAMINA

 

 SODRÉ NETO 



Há alegações de  diferenças entre fosfoetanolamina produzida no Brasil e calcium EAP , olhando a olho nu vemos duas substancias diferentes , contudo , ainda não tivemos a oportunidade de testar e comparar as substancias num espectrômetro. Já a fosfoetanolamina em associação com fosfocolina temos nos EUA o laboratorio Fisher que comercializa: 
http://www.amazon.com/Phosphoethanolamine-Phosphocholine-Phosphatase-Recombinant-Phospho1/dp/B00KCVH1P4

 



 

 

Pequena amostra de artigos científicos já publicados os quais demonstram a eficácia deste remédio tanto em animais como em humanos . 

 

 

http://www.bv.fapesp.br/pt/bolsas/158097/avaliacao-dos-efeitos-antiproliferativos-e-de-apoptose-da-formulacao-lipossomal-dodac-associado-a-fo/

http://www.bv.fapesp.br/pt/bolsas/113156/alquil-fosfatado-sintetico-precursor-dos-fosfolipidios-de-membrana-celular-com-potencial-efeito-anti/

http://www.bv.fapesp.br/pt/bolsas/144190/estudo-da-citotoxicidade-da-formulacao-lipossomal-dodab-com-o-composto-fosfoetanolamina-sintetica-em/

http://www.bv.fapesp.br/pt/bolsas/154548/avaliacao-antitumoral-da-formulacao-lipossomal-dodac-com-o-composto-fosfoetanolamina-sintetica-em-ce/


http://www.bv.fapesp.br/pt/bolsas/158097/avaliacao-dos-efeitos-antiproliferativos-e-de-apoptose-da-formulacao-lipossomal-dodac-associado-a-fo/


http://www.bv.fapesp.br/pt/bolsas/158912/avaliacao-dos-efeitos-antitumorais-da-formulacao-lipossomal-dodacfosfoetanolamina-sintetica-em-mode/

 

 

 

http://www.bv.fapesp.br/pt/auxilios/58595/anti-angiogenic-and-anti-metastatic-activity-of-synthetic-phosphoethanolamine/


High resolution in vivo 31P-MRS of the liver: potential advantages in the assessment of non-alcoholic fatty liver disease.

Jeon MJ, Lee Y, Ahn S, Lee C, Kim OH, Oh BC, Yu U, Kim H.

Acta Radiol. 2015 Sep;56(9):1051-60. doi: 10.1177/0284185114550850. Epub 2014 Sep 30.

PMID:
25270373
2.

IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.

Esmaeili M, Hamans BC, Navis AC, van Horssen R, Bathen TF, Gribbestad IS, Leenders WP, Heerschap A.

Cancer Res. 2014 Sep 1;74(17):4898-907. doi: 10.1158/0008-5472.CAN-14-0008. Epub 2014 Jul 8.

3.

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects.

Ferreira AK, Santana-Lemos BA, Rego EM, Filho OM, Chierice GO, Maria DA.

Br J Cancer. 2013 Nov 26;109(11):2819-28. doi: 10.1038/bjc.2013.510. Epub 2013 Nov 7.

4.

Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.

Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA.

Magn Reson Med. 2014 Jun;71(6):1973-81. doi: 10.1002/mrm.24869. Epub 2013 Jul 22.

PMID:
23878023
5.

Synthetic phosphoethanolamine induces cell cycle arrest and apoptosis in human breast cancerMCF-7 cells through the mitochondrial pathway.

Ferreira AK, Meneguelo R, Pereira A, Filho OM, Chierice GO, Maria DA.

Biomed Pharmacother. 2013 Jul;67(6):481-7. doi: 10.1016/j.biopha.2013.01.012. Epub 2013 Feb 16.

PMID:
23773853
6.

Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine.

Ferreira AK, Freitas VM, Levy D, Ruiz JL, Bydlowski SP, Rici RE, Filho OM, Chierice GO, Maria DA.

PLoS One. 2013;8(3):e57937. doi: 10.1371/journal.pone.0057937. Epub 2013 Mar 14.

7.

Synthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phase.

Ferreira AK, Meneguelo R, Marques FL, Radin A, Filho OM, Neto SC, Chierice GO, Maria DA.

Biomed Pharmacother. 2012 Oct;66(7):541-8. doi: 10.1016/j.biopha.2012.04.008. Epub 2012 May 18.

PMID:
22902646
8.

Nanoassisted laser desorption-ionization-MS imaging of tumors.

Tata A, Fernandes AM, Santos VG, Alberici RM, Araldi D, Parada CA, Braguini W, Veronez L, Silva Bisson G, Reis FH, Alberici LC, Eberlin MN.

Anal Chem. 2012 Aug 7;84(15):6341-5. doi: 10.1021/ac301202q. Epub 2012 Jul 16.

PMID:
22741519
9.

Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.

Zhu L, Kate P, Torchilin VP.

ACS Nano. 2012 Apr 24;6(4):3491-8. doi: 10.1021/nn300524f. Epub 2012 Mar 14.

10.

Anticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: an experimental study.

Ferreira AK, Meneguelo R, Pereira A, Mendonça Filho O, Chierice GO, Maria DA.

Anticancer Res. 2012 Jan;32(1):95-104.

PMID:
22213293
11.

Indexation of cerebral cell membrane phospholipid catabolism by the non-invasively determined cerebral 31-phosphorus neurospectroscopic phosphodiester peak.

Puri BK.

Med Hypotheses. 2012 Feb;78(2):312-4. doi: 10.1016/j.mehy.2011.11.010. Epub 2011 Dec 2.

PMID:
22136945
12.

Hydroxypropyl-β-cyclodextrin copolymers and their nanoparticles as doxorubicin delivery system.

Wang T, Zhang C, Liang XJ, Liang W, Wu Y.

J Pharm Sci. 2011 Mar;100(3):1067-79. doi: 10.1002/jps.22352. Epub 2010 Oct 4.

PMID:
20922814
13.

Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications incancer onset and treatment.

Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC.

PLoS One. 2009 Nov 12;4(11):e7819. doi: 10.1371/journal.pone.0007819.

14.

Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.

Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J.

Magn Reson Med. 2008 Jul;60(1):33-40. doi: 10.1002/mrm.21647.

15.

Comparison of radiolabeled choline and ethanolamine as probe for cancer detection.

Mintz A, Wang L, Ponde DE.

Cancer Biol Ther. 2008 May;7(5):742-7. Epub 2008 May 15.

PMID:
18296919
16.

Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis.

Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H, Deng F.

J Proteome Res. 2007 Jul;6(7):2605-14. Epub 2007 Jun 12.

PMID:
17564425
17.

Role of docosahexaenoic acid in neuronal plasma membranes.

Glomset JA.

Sci STKE. 2006 Feb 7;2006(321):pe6. Review.

PMID:
16467193
18.

A comparison between in vivo and ex vivo HR-MAS 1H MR spectra of a pediatric posterior fossa lesion.

Tugnoli V, Schenetti L, Mucci A, Nocetti L, Toraci C, Mavilla L, Basso G, Rovati R, Tavani F, Zunarelli E, Righi V, Tosi MR.

Int J Mol Med. 2005 Aug;16(2):301-7.

PMID:
16012766
19.

Proton-decoupled 31P MRS in untreated pediatric brain tumors.

Albers MJ, Krieger MD, Gonzalez-Gomez I, Gilles FH, McComb JG, Nelson MD Jr, Blüml S.

Magn Reson Med. 2005 Jan;53(1):22-9.

PMID:
15690498
20.

Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies.

Arias-Mendoza F, Zakian K, Schwartz A, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR; Cooperative Group on MRS Applications in Cancer.

NMR Biomed. 2004 Oct;17(6):382-91. Review.

PMID:
15386624

Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities.

Roberts SJ, Stewart AJ, Sadler PJ, Farquharson C.

Biochem J. 2004 Aug 15;382(Pt 1):59-65.

22.
23.

Magnetic resonance spectroscopy and clinical cancer prognosis.

Zakian KL, Koutcher JA.

Acad Radiol. 2004 Apr;11(4):365-7. No abstract available.

PMID:
15109008
24.

Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy.

Zakian KL, Shukla-Dave A, Meyers P, Gorlick R, Healey J, Thaler HT, Huvos AG, Panicek DM, Koutcher JA.

Cancer Res. 2003 Dec 15;63(24):9042-7.

25.

Response of melanoma tumor phospholipid metabolism to chloroethyle nitrosourea: a high resolution proton NMR spectroscopy study.

Morvan D, Demidem A, Madelmont JC.

Pathol Biol (Paris). 2003 Jul;51(5):256-9.

PMID:
14567189
26.

Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes.

Franks SE, Smith MR, Arias-Mendoza F, Shaller C, Padavic-Shaller K, Kappler F, Zhang Y, Negendank WG, Brown TR.

Leuk Res. 2002 Oct;26(10):919-26.

PMID:
12163053
27.

Flow cytometric determination of lipid peroxidation using fluoresceinated phosphoethanolamine.

Maulik G, Salgia R, Makrigiorgos GM.

Methods Enzymol. 2002;352:80-91.

PMID:
12125379
29.

High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging.

Ziegler A, von Kienlin M, Décorps M, Rémy C.

Cancer Res. 2001 Jul 15;61(14):5595-600.

31.

Tumour phospholipid metabolism.

Podo F.

NMR Biomed. 1999 Nov;12(7):413-39. Review.

PMID:
10654290
32.

Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro.

Bhujwalla ZM, Aboagye EO, Gillies RJ, Chacko VP, Mendola CE, Backer JM.

Magn Reson Med. 1999 May;41(5):897-903.

PMID:
10332871
33.

Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours.

Bell JD, Bhakoo KK.

NMR Biomed. 1998 Nov;11(7):354-9. Review.

PMID:
9859941
34.

Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.

Arndt D, Zeisig R, Eue I, Sternberg B, Fichtner I.

Breast Cancer Res Treat. 1997 May;43(3):237-46.

PMID:
9150903
35.

Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation.

Cabot MC, Zhang Z, Cao H, Lavie Y, Giuliano AE, Han TY, Jones RC.

Int J Cancer. 1997 Mar 4;70(5):567-74.

36.
37.

In vivo and ex vivo study of metabolic and cellular effects of 5-fluorouracil chemotherapy in a mouse mammary carcinoma.

Street JC, Alfieri AA, Traganos F, Koutcher JA.

Magn Reson Imaging. 1997;15(5):587-96.

PMID:
9254003
38.
39.

Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy.

Negendank WG, Padavic-Shaller KA, Li CW, Murphy-Boesch J, Stoyanova R, Krigel RL, Schilder RJ, Smith MR, Brown TR.

Cancer Res. 1995 Aug 1;55(15):3286-94.

40.

Comparison of relative changes in phosphatic metabolites and phospholipids after irradiation.

Merchant TE, Alfieri AA, Glonek T, Koutcher JA.

Radiat Res. 1995 Apr;142(1):29-38.

PMID:
7899557
42.

Phosphorylethanolamine content of human brain tumors.

Kinoshita Y, Yokota A, Koga Y.

Neurol Med Chir (Tokyo). 1994 Dec;34(12):803-6.

43.

Proton magnetic resonance spectroscopy of brain tumors: an in vitro study.

Kinoshita Y, Kajiwara H, Yokota A, Koga Y.

Neurosurgery. 1994 Oct;35(4):606-13; discussion 613-4.

PMID:
7808603
44.

In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells.

Gillies RJ, Barry JA, Ross BD.

Magn Reson Med. 1994 Sep;32(3):310-8.

PMID:
7984063
45.

Characterization of a phosphonium analog of choline as a probe in 31P NMR studies of phospholipid metabolism.

Szwergold BS, Kappler F, Moldes M, Shaller C, Brown TR.

NMR Biomed. 1994 May;7(3):121-7.

PMID:
8080713
46.

The conversion of ethanolamine and of its metabolites to choline in human neuroblastoma clones: effect of differentiation induced by retinoic acid.

Haidar NE, Andriamampandry C, Carrara M, Kanfer JN, Freysz L, Dreyfus H, Massarelli R.

Neurochem Res. 1994 Apr;19(4):457-62.

PMID:
8065502
47.
48.

A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver.

Bell JD, Cox IJ, Sargentoni J, Peden CJ, Menon DK, Foster CS, Watanapa P, Iles RA, Urenjak J.

Biochim Biophys Acta. 1993 Nov 25;1225(1):71-7.

PMID:
8241291
49.

Phospholipid metabolites, prognosis and proliferation in human breast carcinoma.

Smith TA, Bush C, Jameson C, Titley JC, Leach MO, Wilman DE, McCready VR.

NMR Biomed. 1993 Sep-Oct;6(5):318-23.

PMID:
8268064
51.
52.
53.

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo 31P magnetic resonance spectroscopy.

Redmond OM, Bell E, Stack JP, Dervan PA, Carney DN, Hurson B, Ennis JT.

Magn Reson Med. 1992 Oct;27(2):226-37.

PMID:
1461110
54.

Phosphodiesters in saponified extracts of human breast and colon tumors using 31P magnetic resonance spectroscopy.

Merchant TE, Characiejus D, Kasimos JN, Den Otter W, Gierke LW, Glonek T.

Magn Reson Med. 1992 Jul;26(1):132-40.

PMID:
1320725
55.

General features of systemic effects of murine leukemias on phosphate metabolism in liver studied by 31P NMR.

Yushmanov VE, Khristianovich DS, Rozantseva TV, Sibeldina LA.

NMR Biomed. 1992 May-Jun;5(3):107-13.

PMID:
1642967
56.

In vivo and in vitro 31P magnetic resonance spectroscopy of focal hepatic malignancies.

Cox IJ, Bell JD, Peden CJ, Iles RA, Foster CS, Watanapa P, Williamson RC.

NMR Biomed. 1992 May-Jun;5(3):114-20.

PMID:
1322688
57.

Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake.

Ronen SM, Rushkin E, Degani H.

Biochim Biophys Acta. 1992 Mar 20;1138(3):203-12.

PMID:
1547282
58.

Visibility of phospholipids in 31P NMR spectra of human breast tumours in vivo.

Lowry M, Porter DA, Twelves CJ, Heasley PE, Smith MA, Richards MA.

NMR Biomed. 1992 Jan-Feb;5(1):37-42.

PMID:
1550708
59.

Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake.

Ronen SM, Rushkin E, Degani H.

Biochim Biophys Acta. 1991 Oct 16;1095(1):5-16.

PMID:
1657190
60.

Cellular energetics measured by phosphorous nuclear magnetic resonance spectroscopy are not correlated with chronic nutrient deficiency in multicellular tumor spheroids.

Freyer JP, Schor PL, Jarrett KA, Neeman M, Sillerud LO.

Cancer Res. 1991 Aug 1;51(15):3831-7.

PMID:
1855200
Free Article
42.

Phosphorylethanolamine content of human brain tumors.

Kinoshita Y, Yokota A, Koga Y.

Neurol Med Chir (Tokyo). 1994 Dec;34(12):803-6.

43.

Proton magnetic resonance spectroscopy of brain tumors: an in vitro study.

Kinoshita Y, Kajiwara H, Yokota A, Koga Y.

Neurosurgery. 1994 Oct;35(4):606-13; discussion 613-4.

PMID:
7808603
44.

In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells.

Gillies RJ, Barry JA, Ross BD.

Magn Reson Med. 1994 Sep;32(3):310-8.

PMID:
7984063
45.

Characterization of a phosphonium analog of choline as a probe in 31P NMR studies of phospholipid metabolism.

Szwergold BS, Kappler F, Moldes M, Shaller C, Brown TR.

NMR Biomed. 1994 May;7(3):121-7.

PMID:
8080713
46.

The conversion of ethanolamine and of its metabolites to choline in human neuroblastoma clones: effect of differentiation induced by retinoic acid.

Haidar NE, Andriamampandry C, Carrara M, Kanfer JN, Freysz L, Dreyfus H, Massarelli R.

Neurochem Res. 1994 Apr;19(4):457-62.

PMID:
8065502
47.
48.

A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver.

Bell JD, Cox IJ, Sargentoni J, Peden CJ, Menon DK, Foster CS, Watanapa P, Iles RA, Urenjak J.

Biochim Biophys Acta. 1993 Nov 25;1225(1):71-7.

PMID:
8241291
49.

Phospholipid metabolites, prognosis and proliferation in human breast carcinoma.

Smith TA, Bush C, Jameson C, Titley JC, Leach MO, Wilman DE, McCready VR.

NMR Biomed. 1993 Sep-Oct;6(5):318-23.

PMID:
8268064
51.
52.
53.

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo 31P magnetic resonance spectroscopy.

Redmond OM, Bell E, Stack JP, Dervan PA, Carney DN, Hurson B, Ennis JT.

Magn Reson Med. 1992 Oct;27(2):226-37.

PMID:
1461110
54.

Phosphodiesters in saponified extracts of human breast and colon tumors using 31P magnetic resonance spectroscopy.

Merchant TE, Characiejus D, Kasimos JN, Den Otter W, Gierke LW, Glonek T.

Magn Reson Med. 1992 Jul;26(1):132-40.

PMID:
1320725
55.

General features of systemic effects of murine leukemias on phosphate metabolism in liver studied by 31P NMR.

Yushmanov VE, Khristianovich DS, Rozantseva TV, Sibeldina LA.

NMR Biomed. 1992 May-Jun;5(3):107-13.

PMID:
1642967
56.

In vivo and in vitro 31P magnetic resonance spectroscopy of focal hepatic malignancies.

Cox IJ, Bell JD, Peden CJ, Iles RA, Foster CS, Watanapa P, Williamson RC.

NMR Biomed. 1992 May-Jun;5(3):114-20.

PMID:
1322688
57.

Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake.

Ronen SM, Rushkin E, Degani H.

Biochim Biophys Acta. 1992 Mar 20;1138(3):203-12.

PMID:
1547282
58.

Visibility of phospholipids in 31P NMR spectra of human breast tumours in vivo.

Lowry M, Porter DA, Twelves CJ, Heasley PE, Smith MA, Richards MA.

NMR Biomed. 1992 Jan-Feb;5(1):37-42.

PMID:
1550708
59.

Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake.

Ronen SM, Rushkin E, Degani H.

Biochim Biophys Acta. 1991 Oct 16;1095(1):5-16.

PMID:
1657190
60.

Cellular energetics measured by phosphorous nuclear magnetic resonance spectroscopy are not correlated with chronic nutrient deficiency in multicellular tumor spheroids.

Freyer JP, Schor PL, Jarrett KA, Neeman M, Sillerud LO.

Cancer Res. 1991 Aug 1;51(15):3831-7.

PMID:
1855200
Free Article

31P nuclear magnetic resonance studies of Ehrlich ascites tumor cells.

Navon G, Ogawa S, Shulman RG, Yamane T.

Proc Natl Acad Sci U S A. 1977 Jan;74(1):87-91.

82.
83.

Evidence for a mixed function oxidase in the biosynthesis of ethanolamine plasmalogens from 1-alkyl-2-acyl-sn-glycero-3-phosphorylethanolamine.

Wykle RL, Blank ML, Malone B, Snyder F.

J Biol Chem. 1972 Sep 10;247(17):5442-7. No abstract available.

84.

The metabolism of O-phosphorylethanolamine in animal tissues. II. Metabolic regulation of O-phosphorylethanolamine phospho-lyase in vivo.

Fleshood HL, Pitot HC.

Arch Biochem Biophys. 1970 Dec;141(2):423-9. No abstract available.

PMID:
4322284